Interesting article from the Public Health Agency in Canada points out that HSAV is not a reportable STD in Canada:
http://www.phac-aspc.gc.ca/publicat/cjhs/cjhs5-eng.php
Here's a portion for those that don't want to read the entire article:
Epidemiology of Genital HSV in Canada
Since HSV infection is not a reportable STD in Canada, we have limited knowledge of the epidemiology of genital herpes and of the seroprevalence of HSV-2. In a currently unpublished study, Sacks and colleagues used Western blot analysis to determine HSV-2 seroprevalence in a randomized sample of 409 women in labour in a Vancouver hospital between May 1985 and February 1987 (Sacks & Garland, personal communication). Interview data made it possible to draw an association between lifetime number of sexual partners and HSV-2 seropositivity which showed, for example, that women who reported 6-10 partners were over 7 times more likely to be seropositive for HSV-2 (33.3%) than those who reported 1 partner (4.6%), and that 55% of women with more than 10 partners (about 10% of the sample) were seropositive (Table 2). Overall, 20% of women in this "average risk" sample of low to middle class women in Vancouver were seropositive for HSV-2.
Given that a sizeable proportion of young adults in Canada have had 3-5, or more, partners by the time they are 20 years old (for review see Maticka-Tyndale, 1997), and that the number of partners increases with age, we hypothesize that the prevalence of HSV-2 infection in Canada at least parallels that in the mid-range countries identified in Table 1. For example, a Swedish study of 14-15 year old young women found that 0.4% were HSV-2 seropositive; 15 years later, the number was 22% for the same sample (Christenson et al., 1993). In the mid-1980s, HSV-2 seroprevalence in pregnant Swedish women was 27.9% vs. 25.3-34.9% in pregnant Caucasian women in the U.S (see Kroon, 1994). Although these percentages suggest a possible range for the current overall HSV-2 seroprevalence in Canada, the discussion below on risk factors for genital herpes and HSV-2 infection (see Table 3) makes it clear that some sub-groups within the population carry an elevated burden of risk.
